median follow-up of 4 years, RC at 3 years was similar for calLN+ vs calLNe (86% vs 91%; PZ.26). MVA confirmed that adverse radiological features was the only prognostic factor for regional failure (HRZ5.7, PZ.002), while calLN+ (PZ.34) and p16 status (PZ.49) were not predictive. Conclusion: Presence of calLN+ in the post-RT setting is not associated with inferior regional control. Our study affirms that nodes with adverse radiological features (ECE, necrosis, or conglomerate nodal mass[es]) had poorer outcomes. calLN+ alone in the absence of adverse radiological features should not be considered an indicator for post-RT neck dissection. Author Disclosure: S. Rathod: None. S. Huang: None. J. Waldron: None. J. Kim: None. E. Yu: None. L. Tong: None. A. Bayley: None. S. Bratman: None. J. Cho: None. M.E. Giuliani: Travel Expenses; ELECTA. A.J. Hope: Travel Expenses; ELECTA. J.G. Ringash: None. B. O’Sullivan: None. 2758 Elective Nodal Irradiation in Skin Squamous Cell Carcinoma of the Face, Ears, and Scalp J.W. Wray, R.J. Amdur, C.G. Morris, and W.M. Mendenhall; University of Florida, Gainesville, FL Purpose/Objective(s): When treating squamous cell carcinoma (SCC) of the skin of the face, ears, or scalp, the risk of subclinical metastasis to regional nodes can be high, warranting elective nodal treatment. Elective neck dissection, often including parotidectomy, is morbid. Data on the efficacy of elective nodal radiation therapy in this setting are so scarce that there is no publication specifically addressing this subject. The purpose of this study is to evaluate the efficacy and toxicity of elective nodal irradi- ation in patients with skin SCC of the face and scalp who require radiation therapy to the primary site. Materials/Methods: Between 1985 and 2012, 71 adult patients with SCC of the face, ears, and scalp with no evidence of nodal metastasis were treated with elective nodal irradiation in our department. Before treatment, 85% were evaluated with axial imaging. Tumor stage distribution per the 7th edition of the American Joint Committee on Cancer staging manual was as follows: T1, 15%; T2, 34%; T3 1%; and T4 50%. Cancer char- acteristics were as follows: clinical perineural invasion (PNI), 13%; pathological PNI, 78%; recurrent disease, 32%; and positive or close margin, 67%. The median follow-up was 4.5 years for all patients and 6.0 years for living patients. The median radiation dose to the first-echelon nodal area was 65 Gy (range, 38-74 Gy). Involvement of the first echelon nodal area was as follows: parotid, 75%; facial, 37%; retro-auricular, 28%; occipital, 10%; and cervical levels 1 and 2, 8%. Median RT dose to the second echelon nodes was 50 Gy (range, 30-60 Gy). Results: Neck control was achieved in 95.7% of all patients and 96.4% of patients with local control. The 2 failures in patients with local control were within first-echelon nodal areas that received 60 Gy. There were no (0%) grade 3 or higher complications associated with elective nodal irradiation. Conclusion: Elective nodal irradiation in patients with high-risk SCC of the face, ears, and scalp is safe and effective. Author Disclosure: J.W. Wray: None. R.J. Amdur: None. C.G. Morris: None. W.M. Mendenhall: None. 2759 Concurrent Chemotherapy and Intensity Modulated Radiation Therapy for Advanced Squamous Cell Carcinomas of the Head and Neck: What is the Appropriate Chemotherapy? M. Suggs, S.P. Giri, M.R. Kanakamedala, and R.D. Hamilton; University of Mississippi Medical Center, Jackson, MS Purpose/Objective(s): Advanced squamous cell carcinomas (SCE) of the head and neck are usually treated with concurrent chemotherapy. We reviewed the experience at our institution using concurrent chemotherapy and radiation therapy (RT) for advanced squamous cell cancers to assess which chemotherapy is optimal for use in such a regimen. Materials/Methods: We retrospectively reviewed 87 patients with advanced SCE of the head and neck treated between 2007 and 2014. The characteristics are shown in the table. All patients were treated with one of three regimens: concurrent low dose cisplatin (LDC) 40 mg/m2 given weekly (nZ36), cisplatin (C) 100 mg/m2 Q 3 weeks (nZ15) and weekly cetuximab (CX) (nZ36). RT was intensity modulated RT with median dose of 70 Gy given at 2 Gy per fraction daily. Median follow-up was 67 months (10 -120 months). Sites included oropharynx (nZ47) and larynx (nZ28), also hypopharynx (nZ3), nasopharynx (nZ2) and oral cavity (nZ2). Kaplan-Meier estimates of survival were calculated to determine disease-free survival and overall survival differences among these groups. Results: The overall local recurrence rates were 3% in LDC, 0% in C, and 22% in CX groups (PZ.02). Regional recurrence rates were 25% in LDC, 8% in C, and 20% in CX (PZ.18). The distant metastasis rates were 14% in LDC, 20% in C and 11% in CX (PZ.66). Overall median survival was 2.2 years for high dose cisplatin, 2.8 years for cetuximab and has not been reached for weekly cisplatin. Cetuximab had lower grade 3 or 4 toxicity (5.7%) compared to weekly cisplatin (16.7%) or high dose cisplatin (26.7%) (PZ.107). The hazard ratios for risk of death were 2.73, favoring low dose cisplatin over cetuximab (PZ.096), and 3.48, favoring low dose cisplatin over high dose cisplatin (PZ.065). Hazard ratio for death for cetuximab compared to high dose cisplatin is 1.27, slightly favoring Cetuximab (PZ.668). Conclusion: Several regimens have been used in combination with RT for advanced squamous cell cancers of the head and neck. In our experience, low dose cisplatin is superior to cetuximab for locoregional control and survival. The toxicity patterns are different but we did not note significant grade III/IV toxicities. A recent published trial comparing cisplatin and panitumumab, another EGFR inhibitor, also showed that cisplatin was superior (CONCERT-2 trial). We conclude low dose cisplatin should be the drug of choice to be combined concurrently with radiation therapy for advance SCE of the head and neck. If the patient cannot receive cisplatin, then cetuximab is a reasonable alternative. Author Disclosure: M. Suggs: None. S.P. Giri: None. M.R. Kanaka- medala: None. R.D. Hamilton: None. 2760 Definitive Radiation Therapy as an Alternative Treatment for High-Grade Salivary Gland Carcinomas: A Propensity Score Matched Study C.E. Hsieh, 1 C.Y. Lin, 2 N.M. Tsang, 3 J.T.C. Chang, 2 K.H. Fan, 4 L.Y. Lee, 3 H.M. Wang, 3 C.T. Liao, 3 and T.C. Yen 3 ; 1 Chang Gung Memorial Hospital, Taoyuan City 333, Taiwan, 2 Chang Gung Memorial Hospital, Taoyuan 333, Taiwan, 3 Chang Gung Memorial Hospital, Linkou, Taoyuan City 333, Taiwan, 4 Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan Purpose/Objective(s): To investigate the feasibility of definitive radiation therapy (DRT) for high-grade salivary gland carcinomas (HGSGC). Materials/Methods: This multi-institutional retrospective analysis included 277 HGSGC patients who were treated with DRT (nZ58) or surgery with/without adjuvant therapies (nZ219) between 2000 and 2014. The median follow-up time was 62 months for survivors. Adenoid cystic (nZ128) or mucoepidermoid (nZ40) carcinomas were the most common histology subtypes. Minor salivary gland tumors constituted 46 (79%) and Poster Viewing Abstracts 2759; Table 1 Cetuximab (NZ36) Low Dose Cisplatin (NZ36) High Dose Cisplatin (NZ15) Tis 0 (0%) 2 (6%) 0 (0%) T1/T2 26 (14%) 12 (3%) 8 (7%) T3 6 (17%) 16 (46%) 4 (27%) T4 4 (11%) 5 (14%) 3 (20%) N0 5 (14%) 15 (43%) 4 (27%) N1 9 (25%) 5 (14%) 2 (13%) N2 22 (61%) 12 (34%) 8 (53%) N3 0 (0%) 3 (9%) 1 (7%) Volume 93  Number 3S  Supplement 2015 Poster Viewing Session E305